What is AccuLine?
AccuLine is a medical technology innovator dedicated to the early detection of coronary artery disease (CAD). The company has developed CORA, a non-invasive, cost-effective diagnostic solution designed to supersede traditional, often inaccurate, ECG stress tests. By leveraging two novel bio-signals identified within the heart's electrical activity and integrating advanced signal processing algorithms, AccuLine provides a scalable alternative for cardiac screening. The company operates at the intersection of digital health and clinical cardiology, supported by a robust ecosystem of healthcare providers and institutional investors. Its market position is bolstered by strategic partnerships with major healthcare entities, ensuring that its diagnostic tools are grounded in clinical reality and patient-centric outcomes.
How much funding has AccuLine raised?
AccuLine has raised a total of $4.2M across 1 funding round:
Angel/Seed
$4.2M
Angel/Seed (2024): $4.2M with participation from Google for Startups, Maccabi Healthcare Services, eHealth Ventures, and Israel Innovation Authority
Key Investors in AccuLine
Maccabi Healthcare Services
A leading healthcare provider offering comprehensive medical services and digital health solutions, providing a critical clinical testing ground for new medical technologies.
eHealth Ventures
An early-stage digital health fund that specializes in venture building through strategic healthcare partnerships and clinical integration support.
Israel Innovation Authority
A government-backed entity focused on driving technological innovation by providing essential R&D funding and support to high-tech startups.
What's next for AccuLine?
Following this major enterprise-level funding, AccuLine is poised to transition from the development phase into broader clinical validation and commercial deployment. The strategic roadmap focuses on refining the CORA platform's diagnostic accuracy and expanding its footprint within international healthcare systems. By leveraging the expertise of its institutional backers, the company aims to navigate the complex regulatory landscape of medical devices while scaling its operations to meet the urgent global demand for accessible, high-precision cardiac diagnostics. Future growth will likely center on integrating these bio-signal insights into standard clinical workflows, thereby establishing a new gold standard for non-invasive CAD detection.
See full AccuLine company page
